tetano
Editor, Senior Moderator
Ann Hematol
. 2024 Apr 22.
doi: 10.1007/s00277-024-05744-6. Online ahead of print. Multi-center study of COVID-19 infection in elderly patients with lymphoma: on behalf of Jiangsu Cooperative Lymphoma Group (JCLG)
Huayuan Zhu[SUP] 1 2 [/SUP], Xiao Lu[SUP] 3 4 [/SUP], Xiaoping Zhang[SUP] 5 4 [/SUP], Haiying Hua[SUP] 6 4 [/SUP], Jie Zhang[SUP] 7 4 [/SUP], Yuqing Miao[SUP] 8 4 [/SUP], Weiying Gu[SUP] 9 4 [/SUP], Min Xu[SUP] 10 4 [/SUP], Xuzhang Lu[SUP] 11 4 [/SUP], Bingzong Li[SUP] 12 4 [/SUP], Chunling Wang[SUP] 13 4 [/SUP], Haiwen Ni[SUP] 14 4 [/SUP], Jun Qian[SUP] 15 4 [/SUP], Jinning Shi[SUP] 16 4 [/SUP], Maozhong Xu[SUP] 17 4 [/SUP], Guangqi Wu[SUP] 18 4 [/SUP], Yunping Zhang[SUP] 19 4 [/SUP], Qiudan Shen[SUP] 20 4 [/SUP], Zhi Wang[SUP] 21 4 [/SUP], Jianfeng Zhu[SUP] 22 4 [/SUP], Zhen Cheng[SUP] 23 4 [/SUP], Wanchuan Zhuang[SUP] 24 4 [/SUP], Guoqiang Lin[SUP] 25 4 [/SUP], Yongjun Hu[SUP] 26 4 [/SUP], Qiurong Shan[SUP] 27 4 [/SUP], Yifei Chen[SUP] 28 4 [/SUP], Hongchun Qiu[SUP] 29 4 [/SUP], Jianyong Li[SUP] 30 31 [/SUP], Wenyu Shi[SUP] 32 33 34 [/SUP]
Affiliations
Elderly patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we retrospectively described the clinical features and outcomes of the first time infection of Omicron SARS-CoV-2 in 364 elderly patients with lymphoma enrolled in Jiangsu Cooperative Lymphoma Group (JCLG) between November 2022 and April 2023 in China. Median age was 69 years (range 60-92). 54.4% (198/364) of patients were confirmed as severe and critical COVID-19 infection. In univariable analysis, Age > 70 years (OR 1.88, p = 0.003), with multiple comorbidities (OR 1.41, p = 0.005), aggressive lymphoma (OR 2.33, p < 0.001), active disease (progressive or relapsed/refractory, OR 2.02, p < 0.001), and active anti-lymphoma therapy (OR 1.90, p < 0.001) were associated with severe COVID-19. Multiple (three or more) lines of previous anti-lymphoma therapy (OR 3.84, p = 0.021) remained an adverse factor for severe COVID-19 in multivariable analysis. Moreover, CD20 antibody (Rituximab or Obinutuzumab)-based treatments within the last 6 months was associated with severe COVID-19 in the entire cohort (OR 3.42, p < 0.001). Continuous BTK inhibitors might be protective effect on the outcome of COVID-19 infection (OR 0.44, p = 0.043) in the indolent lymphoma cohort. Overall, 7.7% (28/364) of the patients ceased, multiple lines of previous anti-lymphoma therapy (OR 3.46, p = 0.016) remained an adverse factor for mortality.
Keywords: BTK inhibitors; CD20 antibody; CLL; COVID-19; Elderly patients with lymphoma; Omicron SARS-CoV-2.
. 2024 Apr 22.
doi: 10.1007/s00277-024-05744-6. Online ahead of print. Multi-center study of COVID-19 infection in elderly patients with lymphoma: on behalf of Jiangsu Cooperative Lymphoma Group (JCLG)
Huayuan Zhu[SUP] 1 2 [/SUP], Xiao Lu[SUP] 3 4 [/SUP], Xiaoping Zhang[SUP] 5 4 [/SUP], Haiying Hua[SUP] 6 4 [/SUP], Jie Zhang[SUP] 7 4 [/SUP], Yuqing Miao[SUP] 8 4 [/SUP], Weiying Gu[SUP] 9 4 [/SUP], Min Xu[SUP] 10 4 [/SUP], Xuzhang Lu[SUP] 11 4 [/SUP], Bingzong Li[SUP] 12 4 [/SUP], Chunling Wang[SUP] 13 4 [/SUP], Haiwen Ni[SUP] 14 4 [/SUP], Jun Qian[SUP] 15 4 [/SUP], Jinning Shi[SUP] 16 4 [/SUP], Maozhong Xu[SUP] 17 4 [/SUP], Guangqi Wu[SUP] 18 4 [/SUP], Yunping Zhang[SUP] 19 4 [/SUP], Qiudan Shen[SUP] 20 4 [/SUP], Zhi Wang[SUP] 21 4 [/SUP], Jianfeng Zhu[SUP] 22 4 [/SUP], Zhen Cheng[SUP] 23 4 [/SUP], Wanchuan Zhuang[SUP] 24 4 [/SUP], Guoqiang Lin[SUP] 25 4 [/SUP], Yongjun Hu[SUP] 26 4 [/SUP], Qiurong Shan[SUP] 27 4 [/SUP], Yifei Chen[SUP] 28 4 [/SUP], Hongchun Qiu[SUP] 29 4 [/SUP], Jianyong Li[SUP] 30 31 [/SUP], Wenyu Shi[SUP] 32 33 34 [/SUP]
Affiliations
- PMID: 38649594
- DOI: 10.1007/s00277-024-05744-6
Elderly patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we retrospectively described the clinical features and outcomes of the first time infection of Omicron SARS-CoV-2 in 364 elderly patients with lymphoma enrolled in Jiangsu Cooperative Lymphoma Group (JCLG) between November 2022 and April 2023 in China. Median age was 69 years (range 60-92). 54.4% (198/364) of patients were confirmed as severe and critical COVID-19 infection. In univariable analysis, Age > 70 years (OR 1.88, p = 0.003), with multiple comorbidities (OR 1.41, p = 0.005), aggressive lymphoma (OR 2.33, p < 0.001), active disease (progressive or relapsed/refractory, OR 2.02, p < 0.001), and active anti-lymphoma therapy (OR 1.90, p < 0.001) were associated with severe COVID-19. Multiple (three or more) lines of previous anti-lymphoma therapy (OR 3.84, p = 0.021) remained an adverse factor for severe COVID-19 in multivariable analysis. Moreover, CD20 antibody (Rituximab or Obinutuzumab)-based treatments within the last 6 months was associated with severe COVID-19 in the entire cohort (OR 3.42, p < 0.001). Continuous BTK inhibitors might be protective effect on the outcome of COVID-19 infection (OR 0.44, p = 0.043) in the indolent lymphoma cohort. Overall, 7.7% (28/364) of the patients ceased, multiple lines of previous anti-lymphoma therapy (OR 3.46, p = 0.016) remained an adverse factor for mortality.
Keywords: BTK inhibitors; CD20 antibody; CLL; COVID-19; Elderly patients with lymphoma; Omicron SARS-CoV-2.